These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32424917)

  • 1. Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?
    Hagström H
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1204-1205. PubMed ID: 32424917
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply.
    Moolla A; Tomlinson JW
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1205-1206. PubMed ID: 32424931
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
    Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
    Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research advances in diagnosis of non-alcoholic fatty liver disease].
    Wang JH; Yu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD.
    Khan RS; Newsome PN
    Aliment Pharmacol Ther; 2017 Nov; 46(9):899-900. PubMed ID: 29023886
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations.
    Troisi J; Pierri L; Landolfi A; Marciano F; Bisogno A; Belmonte F; Palladino C; Guercio Nuzio S; Campiglia P; Vajro P
    Nutrients; 2017 May; 9(5):. PubMed ID: 28492501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
    Caussy C; Soni M; Cui J; Bettencourt R; Schork N; Chen CH; Ikhwan MA; Bassirian S; Cepin S; Gonzalez MP; Mendler M; Kono Y; Vodkin I; Mekeel K; Haldorson J; Hemming A; Andrews B; Salotti J; Richards L; Brenner DA; Sirlin CB; Loomba R;
    J Clin Invest; 2017 Jun; 127(7):2697-2704. PubMed ID: 28628033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
    PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis?
    Horn P; Newsome PN
    Aliment Pharmacol Ther; 2020 May; 51(10):987-988. PubMed ID: 32338785
    [No Abstract]   [Full Text] [Related]  

  • 13. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale.
    Mann JP; Vreugdenhil A; Socha P; Jańczyk W; Baumann U; Rajwal S; Casswall T; Marcus C; van Mourik I; O'Rahilly S; Savage DB; Noble-Jamieson G; Lacaille F; Dabbas M; Dubern B; Kelly DA; Nobili V; Anstee QM
    Contemp Clin Trials; 2018 Dec; 75():67-71. PubMed ID: 30408605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply.
    Henson JB; Corey KE
    Aliment Pharmacol Ther; 2020 May; 51(10):988-989. PubMed ID: 32338780
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kang MK; Park JG; Lee HJ; Kim MC
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development.
    Xu Y; Han J; Dong J; Fan X; Cai Y; Li J; Wang T; Zhou J; Shang J
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
    Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.